Auriga's Thoratec Preparing to Overcome Competitive Hurdle


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


According to a research report published by Auriga, Thoratec Corporation's (NASDAQ: THOR) HeartMate II is experiencing an increased rate of thrombosis based on recent checks on the VAD space. Auriga commented that, “The increased thrombosis rate is surprising given HM II's long history, low published rate of thrombosis (most recent ISHLT data was 0.025 Events/PPY) and high number of implants (8,000+ WW). Given the long track record, we do not view the uptick in thrombosis as a major setback for HM II, but as a reminder that thrombosis is not unique to any device. We expect THOR will be able to address the issue, just as HeartWare (HTWR, Hold) found a solution to its (well-publicized) thrombosis problem.”Auriga maintains its Hold rating and $35.00 PT on Thoratec Corp., which closed yesterday at $29.68.

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorReiterationAnalyst RatingsAuriga